A risk score model was developed to predict chemotherapy-associated venous thromboembolism (VTE). Initial risk factors included were site of the malignancy, platelet count >350,000/microL, hemoglobin concentration <10 g/dL, leukocyte count >11,000/microL, and body mass index ≥35 kg/m2 [1].
This model was expanded to include two additional variables: soluble P-selectin and D-dimer levels, with resulting scores varying from zero to eight [2].
In a retrospective study, the cumulative VTE probability after six months was 35, 20, 10, and 1 percent for those with the highest (≥5), high-intermediate (4), low-intermediate (3), and lowest (zero) scores, respectively.
Source:
This model was expanded to include two additional variables: soluble P-selectin and D-dimer levels, with resulting scores varying from zero to eight [2].
In a retrospective study, the cumulative VTE probability after six months was 35, 20, 10, and 1 percent for those with the highest (≥5), high-intermediate (4), low-intermediate (3), and lowest (zero) scores, respectively.
Source:
- Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902.
- Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377.